SEC Form 4Coverage since Jun 1, 2026
$NBP insider trading
Over the last 12 months, NovaBridge Biosciences insiders reported no purchases and 3 sales totaling $23K across SEC Form 4 filings.
- Bought · 12m
- — 0 events
- Sold · 12m
- $23K 3 events
- Events · 12m
- 3 Form 4 filings, grouped
- Insiders · 12m
- 2 distinct reporters
- 10b5-1 share
- 0% pre-arranged plans
Side
Price · $NBP · 12Mvia TradingView
Top insiders · 12m
Xu Cong ClaireSVP, Clinical Development2× · $18K
Dennis Phillip AndrewChief Medical Officer1× · $6K
All insider trades
3 events
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jul 6, 2026 | Xu Cong ClaireSVP, Clinical Development · O | ▼ Sale | 4,485 | $0.89 | $4K | -1.5% | — |
| Jun 18, 2026 | Dennis Phillip AndrewChief Medical Officer · O | ▼ Sale | 8,494 | $0.66 | $6K | -5.1% | — |
| Jun 1, 2026 | Xu Cong ClaireSVP, Clinical Development · O | ▼ Sale | 3,494 | $3.94 | $14K | -1.2% | — |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $NBP feed.